
    
      Part A of the study is an open-label design with dosing of Levodopa for 3 days followed by
      SAGE-217 for 4 days.

      Part B of the study is an open-label design with evening dosing of SAGE-217 for 7 days as an
      adjunct to antiparkinsonian agent(s).
    
  